XOMA Royalty (NASDAQ:XOMA) CFO Sells $155,836.70 in Stock

Key Points

• XOMA Royalty CFO Thomas Burns sold 4,330 shares of stock, totaling $155,836.70, resulting in a 12.58% decrease in his holdings.
• The company reported $0.48 EPS for the latest quarter, significantly surpassing estimates, with revenues of $13.13 million against an estimate of $9.39 million.
• Several research firms have recently upgraded XOMA's rating to "buy," with a consensus target price of $69.50.

XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) CFO Thomas Burns sold 4,330 shares of XOMA Royalty stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total value of $155,836.70. Following the sale, the chief financial officer directly owned 30,079 shares of the company's stock, valued at $1,082,543.21. This represents a 12.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

XOMA Royalty Price Performance

NASDAQ:XOMA traded up $0.44 during trading hours on Tuesday, hitting $37.60. 57,679 shares of the company's stock traded hands, compared to its average volume of 45,916. The firm has a market cap of $454.58 million, a P/E ratio of -24.26 and a beta of 0.98. XOMA Royalty Corporation has a 52 week low of $18.35 and a 52 week high of $38.48. The business's fifty day simple moving average is $31.10 and its two-hundred day simple moving average is $26.22. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.60. The company had revenue of $13.13 million during the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%. On average, research analysts anticipate that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on XOMA. HC Wainwright reissued a "buy" rating and set a $104.00 price objective on shares of XOMA Royalty in a research note on Wednesday, May 28th. Wall Street Zen raised XOMA Royalty from a "hold" rating to a "buy" rating in a research note on Monday, August 11th. Finally, Zacks Research raised XOMA Royalty from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, XOMA Royalty currently has a consensus rating of "Buy" and a consensus target price of $69.50.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of XOMA. Bank of America Corp DE increased its holdings in shares of XOMA Royalty by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after buying an additional 2,009 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of XOMA Royalty by 3.8% in the fourth quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company's stock worth $377,000 after buying an additional 527 shares during the period. GAMMA Investing LLC increased its holdings in shares of XOMA Royalty by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,585 shares during the period. CM Management LLC increased its holdings in shares of XOMA Royalty by 16.4% in the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock worth $1,276,000 after buying an additional 9,000 shares during the period. Finally, Deutsche Bank AG increased its holdings in shares of XOMA Royalty by 5,087.9% in the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after buying an additional 6,309 shares during the period. Hedge funds and other institutional investors own 95.92% of the company's stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.